×
Surrozen Total Liabilities 2021-2024 | SRZN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Surrozen total liabilities from 2021 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
View More
Surrozen Total Liabilities 2021-2024 | SRZN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Surrozen total liabilities from 2021 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$79.8B
Takeda Pharmaceutical (TAK)
$42.6B
Sandoz Group AG (SDZNY)
$19.5B
Merck (MKKGY)
$19.1B
Astellas Pharma (ALPMY)
$18.3B
United Therapeutics (UTHR)
$16.6B
Summit Therapeutics (SMMT)
$14B
Neurocrine Biosciences (NBIX)
$12.7B
Shionogi (SGIOY)
$12B
Catalent (CTLT)
$11.1B
Madrigal Pharmaceuticals (MDGL)
$7.6B
Orion OYJ (ORINY)
$6.7B
Corcept Therapeutics (CORT)
$6B
Ionis Pharmaceuticals (IONS)
$5.4B
Crinetics Pharmaceuticals (CRNX)
$5.2B
PTC Therapeutics (PTCT)
$3.3B
Dyne Therapeutics (DYN)
$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
Soleno Therapeutics (SLNO)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.2B
NewAmsterdam Pharma (NAMS)
$1.9B
Xencor (XNCR)
$1.8B
Recursion Pharmaceuticals (RXRX)
$1.6B
Evotec AG (EVO)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Harrow (HROW)
$1.5B
Indivior (INDV)
$1.5B
Guardian Pharmacy Services (GRDN)
$1.5B
Ocular Therapeutix (OCUL)
$1.4B